TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 1 | 4 | 9 | 6 | 39 | 86 | -1 | 24 |
| P | %wins | 100 | 100 | 100 | 100 | 100 | 0 | 83 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/29/22 18:18 | 11/28/22 | OABI | Omniab, Inc. | DE | Health | Biolab | Commercial Physical & Biologi | Gustafson Kurt A | CA | O | EVP,Fina | P | 28 | 2.81 | 0 | 10 | 6 | 170 | D | ||||||||||||||
8/10/11 20:31 | 8/9/11 | HALO | Halozyme Therapeutics Inc | DE | Health | BioPrd | Biological Products, (No Diag | Gustafson Kurt A | CA | O | VP,CFO | P | 47 | 5.88 | 3 | 8 | New | 8 | D | -19 | -17 | -15 | -9 | -13 | -15 | -12 | 5 | 4 | 9 | 6 | 39 | 86 | -1 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |